Insights On Drug Development

  1. The World Outside Influencing Your Outsourcing Internals 6/26/2025

    Tariffs, geopolitical gyrations, (pending) laws such as the BIOSECURE Act; all affect your outsourcing optionality and decision-making. Our panel of internationally savvy biopharma executives provide some guiding insights.

  2. Creating Your ADC Supply Chain 6/26/2025

    Antibody-drug conjugates (ADCs) are on the rise. Supply chains to serve ADC developers can be complicated, and spread out. Reza Oliyai has some key interpretations of how these therapies can string together optimal - and at times far-reaching - supply chains.

  3. Your CDMO Knows A Lot - Are You Listening? 6/26/2025

    Our three experienced panelists weigh in on how sponsors should take advantage of what CDMOs know from experience in quality, regulatory, and other aspects of development and processing.

  4. CDMO SOWs Must (Re-)Align With New Project Realities 6/26/2025

    Decades of experience in cell and gene therapy outsourcing have taught Donna Rill, Chief Technology Officer, Triumvira Immunologics, that the key to success is ensuring CDMOs and sponsors understand the need to continuously align SOWs with the variances as projects move forward.

  5. It's Not What You Deserve, It's What You Negotiate 6/26/2025

    Seshu Tummala of Uniquity Bio and Reza Oliyai of Oliyai Consulting Corporation discuss how to achieve your (at times evolving) goals and meet the needs of your CDMOs.

  6. Budgeting Key Component In Biologics Flexibility At CDMOs 6/26/2025

    You want flexibility in scheduling, contracts, and the entire CDMO relationship. While money can't buy you love, it can go a long way in getting that more flexible partnership.

  7. An Intro To CDMO Flexibility 6/26/2025

    Seshu Tummala, Executive Director at Uniquity Bio discusses some of the components of "CDMO flexibility" when it comes to biologics outsourcing relationships.

  8. Outsourcing Biologics Comes With "Demands" 6/26/2025

    Chief Editor Louis Garguilo opens the discussion with our panelists on the state of biologics outsourcing, and the "must haves" for sponsors of their CDMOs.

  9. Negotiating With Your CDMOs 6/26/2025

    Reza Oliyai, President and CEO, Oliyai Consulting Corporation, informs our Outsourced Pharma Live attendees of his thoughts on negotiating to get the outsourcing relationship and scope of work you need at your CDMO.

  10. Where CDMOs Can Improve For CGT Customers? 6/26/2025

    Donna Rill, Chief Technology Officer, Triumvira Immunologics, has advice for CDMOs to improve their service to CGT customers, and conversely, where drug developers can improve as well.